DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Desjardins - 1 Frederic Tremblay - 1 Canaccord - 1 Katie Lachapelle - 1 Meaghan - 1 Valneva - 1 Lyme - 1 Christian Glennie - 1
Top related locs:
U.S Toronto James Bay Valneva France Paris
Top related orgs:
CNBC Pro - 1 Battery Metals - 1 Valneva - 1 Pfizer - 1 Analysts - 1 Guggenheim Securities - 1

Search resuls for: "Evan Wang"


2 mentions found


☆ Check out these 11 U.S.-listed foreign stocks — which analysts give over 100% upside
  + stars: | 2024-09-11 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +3 min
The table below lists 11 stocks that analysts give over 100% upside potential in their local currency over the next 12 months. Investors should note that these stocks are exposed to foreign exchange fluctuations. Although the company has a primary listing on the Toronto stock exchange, the stock is also traded on U.S. stock exchanges . Valneva France-based Valneva has the second-biggest consensus upside potential on the list, at 213%. Stifel's price target of 9 euros ($9.94) a share indicates a 201% upside potential.
Persons: Desjardins, Frederic Tremblay, Canaccord, Katie Lachapelle, Meaghan, Valneva, Lyme, Christian Glennie, Evan Wang Organizations: CNBC Pro, Battery Metals, Valneva, Pfizer, Analysts, Guggenheim Securities Locations: U.S, Toronto, James Bay, Valneva France, Paris
☆ US panel backs GSK vaccine, heating up RSV vaccine race
  + stars: | 2023-03-01 | by ( Khushi Mandowara Mariam Esunny | Khushi Mandowara | Mariam Esunny | ) www.reuters.com   time to read: +2 min
The panelists seemed significantly more confident about the demographic profile used during the GSK study in comparison to Pfizer's (PFE.N) RSV vaccine, which was recommended by the FDA panel on Tuesday. Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which is estimated to be over $5 billion and could exceed $10 billion by 2030, according to analysts. There is currently no approved vaccine to prevent lower respiratory tract disease caused by RSV in older adults, which causes death of 14,000 adults aged 65 and older annually in the United States. In October, late-stage data of GSK's RSV vaccine showed it to be 82.6% effective in preventing lower respiratory tract disease in people aged 60 and over, while Pfizer's vaccine was 66.7% effective. If approved, we estimate peak sales for GSK vaccine to be about $2.8 billion globally, said Evan Wang, Guggenheim Securities analyst, ahead of the panel vote.
0 next >>
Total: 2